FLI1 and Ewing sarcoma: Proteasome inhibition has also been established as a specific vulnerability of Ewing sarcoma (EWS-FLI1) [46], suggesting a particular susceptibility of this related translocation-associated sarcoma to proteasome inhibitor drug intervention.